BACKGROUND:In1993, interferon beta-1bbecamethe firstof4self-injectable multiplesclerosis (MS) drugstobeapproved by theU.S. Food and DrugAdministration.Initially covered as amedical expense, selfinjectable MS drugsare increasingly considered specialtypharmaceuticals and are oftencovered underthe pharmacybenefit.Self-injectable MS drugs are expensive, costing approximately $2,000 per month per patient in 2007.
•P reviousa dministrative claimsr esearchf ound an incidence of multiple sclerosis( MS)d iagnosis code 340( International Classification of Diseases,N inth Revi sion,C linicalM odification, ICD-9-CM)o f1 40 per1 00,000 patients in 2004 anda verage annual medicalcarec ostso f$ 12,879 perMSpatient, 64.8%o f whichwas attributable to prescription drugs. 10 •T otal annual inflation-adjustedMStreatment costsincreased by 35%over the10-year period,from$9,515per patientin1995to $12,879in2004. 10 •P harmacyc laimsa ccounted for9 7.5% of totalm edical and pharmacy benefit spending on the4self-injectable MS drugsin 2004,98.0% in 2005 and2006, and98.8% in thefirst 9months of 2007.
•T he mean AW Pp er memberp er month (PMPM) fort he 4s elf-injectable drugsi ncreased by 57%f rom$ 1.11 PMPM in thef irst quartero f2 004 to $1.74P MPMi nt he thirdq uarter of 2007,o ra na veragea nnuali ncreaseo fa pproximately1 2%. Sinceutilization wasessentiallyflatat82-83 claimsper 100,000 members permonth during the45-month measurement period, pricerather than utilization accountedf or this 57%increasein PMPM cost.
•M embers paid am edian cost-share of approximately1 %o fthe totalcost of self-injectable MS drugsover theperiodfrom2004 throughthe first9monthsof2007.
M ultiples clerosis( MS)i sap rogressivea utoimmune diseaset hata ttacks thec entral nervouss ystem, causingar ange of symptomst hatc an progress to disability.M Sa ffectsa pproximately4 00,000 Americans. 1 Because of thes ubclinical disease activity earlyi nt he disease process,c urrent expert opinioni st hatt reatment of MS should be initiatedearly with adisease-modifyingagent (DMA)f or the best outcomes, includingr educingr elapsesa nd slowingt he progressiono fd isability. [2] [3] [4] Therapyi sg enerallyi nitiated with either interferonb etao rg latiramera cetate (DMAs) andi sc ontinuedindefinitely. 3, 5, 6 Thereare no guidelines to recommend one self-injectable MS therapyoveranother. 5, 6 Currently, 6D MAsare approvedbythe U.S. Food andDrug Administration (FDA)for treatingMS(Table1 ). The4self-injectabled rugs-intramuscular( IM)i nterferonb eta-1a (Avonex), subcutaneous (SC) interferonbeta-1a (Rebif),interferon beta-1b (Betaseron),a nd glatiramer acetate( Copaxone)-aret he focus of this analysis.N atalizumab( Tysabri) andm itoxantrone (Novantrone) arei nfusedi ntravenously,a re typicallya dministeredi na no utpatients etting, anda ccount forl ess than0 .2% of DMAp harmacyc laims. Of note,2o ft he FDA-approved medicationsa re thes amec hemicale ntity( interferonb eta-1a) produced by similarrecombinant DNAtechnology butdiffer in therouteofadministrationand dosing regimen. 7 Therapyi sg enerallyi nitiated with 1o ft he 4s elf-injectable products andi sd eterminedo nt he basiso fp atient and clinicianp referencea sw ella sr esponse. Thesea gentsa re considered immunomodulatorsa nd worko nt he inflammatory aspect of MS as well as otherp athways. In general, theD MAs reduce attack ratesb ya bout 30%a nd decrease thea ccumulation of lesions( areaso fd emyelinationo fn eurons in the braina nd spine) detected by magnetic resonancei maging (MRI). [3] [4] [5] Despitet he anti-inflammatorye ffectso ft hese medications, they have notb eens hown to completelyp revent the progressiont odisability forp atients; however,t heyl ikelys low progression. 5, 8 Side effectso ft he medicationsi nclude flu-likes ymptoms, injections iter eactions,a nd increasesi nl iver enzymes, which generallydisappearinthe firstfew months of treatment. 2 These side effectscan make compliance achallenge forsomepatients. Patientsm ay develop neutralizing antibodies to thei nterferon products,w hich potentiallym aket he drugsl ess effectiveo ver time. [5] [6] [7] Neutralizing antibodies develop more frequentlytointerferonbeta-1b than to either of theinterferonbeta-1a products,and more frequentlytoSCthantoIMinterferonbeta-1a. 7 Thepersistenceo fn eutralizing antibodies also differs by product, with interferonbeta-1a associated with greaterpersistence thaninterferonbeta-1b. A2007study reported thatneutralizingantibodiesa ffected relapser ates andM RI findingsb ut notd isability measures. 9 Considerationo ft he immunogenicity of thei nterferonp roductsm ay be warranted wheni nitiatingt herapy or if therapyisfailing. 5, 7 Because of thec urrent recommendationf or life-longp harmacotherapy, it is importantt ou nderstandt he pharmacotherapyc ost implications.Prescotte ta l. foundt hatt he average annual cost forM Sp atientsw as $12,879i n2 004, 64.8%o f whichw as attributable to thec ost of prescription drugsa nd 61.4%f or theD MAss pecifically. 10 Foras ubseto fM Sp atients whohad at least1pharmacyclaim foraDMAin2004( 57.5%), them edicatione xpenditure accountedf or 75.3%o ft he total medicalcosts. 10 Because of thesignificantmedicationcost associated with thet reatment of MS,i nsurersa nalyze claims data to evaluate medication utilization,medicationexpenditure,regional variations,a nd membero ut-of-pocket( OOP) costst ob etter understand themanagementconsiderationsassociatedwithMS pharmacotherapy. In addition,i nsurerss houldu nderstandt he proportion of self-injectable MS spendp rocessed throught he medicala nd pharmacy benefit,a st hisi nformation can lead to better management of thesemedications.
To ourknowledge,limited information is available on trends in MS utilization,c ost,a nd thep roportiono fe xpenditures attributable to pharmacy andm edical benefits. To respond to this need,P rime Therapeutics,ap harmacyb enefitsm anager with approximately1 0million membersthroughout theUnited States,a nalyzedi ts self-injectable MS pharmacy benefit utilization andexpenditure data overall andbyregionf or a4 5-month period beginningi nJ anuary 2004 ande ndingi nS eptember 2007.
■■ Market Sharefor Self-InjectableMSDrugs in theThird Quarterof2007
From pharmacy claims, the4s elf-injectable MS drugsw ere identified from theN ationalD rugC odef ield usingt he GenericP roduct Identifier (GPI, Medi-Span).G PI beginning 624030604564 identified IM interferonb eta-1a;G PI beginning 624030605021 identified interferonb eta-1b;G PI beginning 624000301064 or 624000301021 identified glatiramer acetate; andG PI beginning6 24030604520 identified SC interferon beta-1a(Table1 ).
Figures1and2s howt he variationi nm arkets hare for membersw ithp harmacyb enefitsd uringt he thirdq uarter of 2007,m easuredb yp harmacyc laim counta nd actualp aid ingredient cost afters ubtractingp harmacyn etworkd iscounts. Data fort he thirdq uartero f2 007r epresent approximately 9million members. Forall analyses,eachmail orderclaim (dispensed with up to a9 0-days upply) wasw eighteda s3c laims, ande achc ommunity pharmacy claim (dispensed with up to a 34-daysupply) wascountedas1claim.F ormulary medications included IM interferon beta-1a, SC interferon beta-1a, andglatiramerfor membersinall geographic regions, with theexception of 51.8%o ft he CentralP lainsm embersw hose formularyw as limited to IM interferon beta-1aand glatiramer.
In all geographic regions,glatiramerand IM interferonbeta-1a hadt he largestm arkets hare,t ogethera ccountingf or 59.7%t o www.amcp.orgV ol. 13 Othercontributingfactors formedicationselectioncould include differences ind osingf requency,r outeo fa dministration, formation of neutralizing antibodies,and theperceived efficacy of the products. Findings forthe analysis of paid ingredient costsw eren early identicaltotheutilization analysis results (Figure 2) .Thatwould be expected,a st he average wholesalep rices( AW Ps)p er pharmacy claimamong themedications were similarduringthe third quarterof2007(Table2 ).
■■ Utilization andCostTrendsfor Self-Injectable MS Drugs
Analysis of priceinflation from thefirst quarterof2004 through thet hird quartero f2 007s howedt hatp ricesf or all thes elfinjectable MS products increaseds ubstantiallyb ya mounts rangingfrom34.7% to 54.8%, yielding ac ompound annualized rate of more than1 2% (Table 2) .F or comparison,a na nalysis conducted by theAmerican AssociationofRetired Personsfound that prices forw idelyu sedb rand-named rugs increasedb y 6%-7%a nnuallyb etween 2004 and2 006.
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Overall inflation as measured by theC onsumerP rice Indexd uringt his period was approximately3 %per year.
Theo verall trendi nm edicatione xpenditure is composed of utilization,p rice inflation,a nd medicationm ix (i.e.,t he proportion of use of higher-cost vs.lower-cost products). Inflation andm ix influence pricep er pharmacy claim.I nt hist herapy class, themix effectsare smalland thecostsper pharmacy claim forthe 4MSm edications arerelativelye quivalent( Table2 ). The compoundinflation increase in unit priceof9%to13% mirrored the13% annualized increase in priceper claim(Table2,Figure3, Table3 ). Therefore, thec ost trendf or thesem edications is primarilyafunction of priceinflation andutilization.
As showni nF igure3 ,w hich represents claimsf or approximately 3m illion membersf or whom continuous data were availableo verthe past 3y ears,per capita utilization (numbero f claims per1 00,000 membersper month) hasremainedrelatively stable since2004. AW Pingredientcost perclaim produced most of thei ncreasei nt otal perc apitae xpenditure (AWP perm emberp er month[ PMPM]).A st he quantity dispensedp er claim decreaseds lightlyt hroughout this time frame, pricei nflation wast he majord rivero ft he increase in expenditure. AW Pw as usedinthese analyses because contract rateswithpharmaciesare confidentialand only brand-name products areincludedinthis analysis.Inaddition, accordingtothe U.S. CongressionalBudget Office," AW Ptends to have aconsistentrelationshipwithaverage transactionpricesfor [brand]drugs."
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From thef irst quartero f2 004t hrought he thirdq uartero f 2007,the compound annualizedincreases in AW PPMPMexpenditure,A WP ingredient cost perclaim,and number of claims per 100,000 membersp er monthf or self-injectable MS medications were 13.6%, 13.0%, and0.5%, respectively(Table3and Figure 3) 
■■ Member Out-Of-PocketCostTrends forSelf-InjectableMSDrugs
As theself-injectable MS totalAWP perpharmacyclaim increased substantially to $2,119,the medianO OP cost perc laim paid by membersincreased from $20inthe firstquartero f2 004t o$ 30 in thefirst quarterof2007 (Figure 4 ).For allof2004,the median OOPc ost perc laim was$ 15 andm embersp aidam eano f$ 52 OOPper claim, representing3.7%oftotal MS drug cost (Table 4) . Theproportionofmember cost-share wasessentiallyunchanged in 2007 at 3.8%,withamedianOOP cost of $25per claimand a mean OOPof$79 perclaim. Seasonal trends in OOPc ostsa re apparent, especially when followingthe mean (Figure4 ). Thebulkofthe MS member OOP costsare spentinthefirst quarterofthe calendar year anddecline throughout they eara ss omem embers reachp harmacyd eductiblesa nd OOPm aximums. Ap ortion of membersp ay fort heir entire therapiesOOP or have abenefit design thatrequires them to payf or ap ercentageo ft he medication.T hish ighlys kewed distribution in OOPc ost pushesthe mean higher than the7 5th percentile.For example, during thefirst quarterof2007, 5% paid ≥ $517 (95thp ercentile), and1 0% paid ≥ $355 (90thp ercentile), while7 5% paid $100 or less (75thp ercentile) (datan ot shown). During thethird quartero f2 007, 5% paid ≥ $100 (95thpercen -tile), and75% paid $35orless (75thpercentile).
■■ Trendsinthe ProportionsofSelf-Injectable MS Drug ExpenditureProcessed Throughthe Medical Versus Pharmacy Benefit
An analysis of an integrated medicala nd pharmacy claims data setfor 1.8million membersenrolledinasinglecommercialstate Blue CrossBlueShield(BCBS)health plan in theNorthernPlains region evaluatedthe proportionsofself-injectable MS medication expenditures thatwereprocessed throughthe medicaland pharmacy benefits. These1 .8 million membershad theirclaimspaid by as ingleB CBSp ayerf or both fullyi nsured ands elf-insured members. Self-injectable MS drugsw erei dentifiedf romm edicalclaimsusing Healthcare Common ProcedureCodingS ystem codes: J1595f or glatiramer, J1830f or SC interferon beta-1b, Q3026f or SC interferon beta-1a, andQ 3025 andJ 1825 forI M interferon beta-1a. J1825isgenerally usedonlyf or IM interferon beta-1a, butSCinterferonbeta-1a does occasionally appearbilled under this code ( Table 1) . As showni nF igure5 ,2 .5%o ft he totale xpenditurew as processed throught he medicalb enefit in 2004.I n2 007, selfinjectable MS spendp rocessed throught he medicalb enefit had declined by more than 50%from2 004 to less than 1.2% of the totalspend.For this insurerand others that process themajority of self-injectable MS medications throughtheir pharmacy benefit manager, medicationm anagement (e.g., clinicalp rograms, benefit design)s houldb ef ocusedo nt he pharmacy benefit instead of themedical benefit.
■■ Discussion
Multiple sclerosisisadebilitatingdisease andthe goal of current therapiesist odecreasethe patient'sn umbero fattacks in hopes of slowing the progression to disability. [2] [3] [4] Multiple sclerosis pharmaco therapy is expensive, and now consumes $1 of every $40 pharmacy benefit dollars to pay for 82.2 claims per month per 100,000 insured members. Utilization of these self-injectable products has been relatively constant in the past 3 years. In our analysis of a single insurer for which we have both pharmacy and medical data trended back to 2004, the expenditure tends to fall almost entirely under the pharmacy benefit. A similar proportion of medical and pharmacy self-injectable MS drug expenditure existed for state Blues plans in the Midwest and South (data not shown). Total medication expenditure for these products over the past 3 years has increased 13.6% annually and has been almost entirely driven by price increases. Multiple sclerosis medication price inflation is 4 times the standard inflationary rate for all consumer goods and 2 times the inflation rate for commonly used branded prescription medications.
While the median OOP cost per pharmacy claim for these 4 self-injectable MS drugs has remained constant at about 1% of the total price of these drugs, when calculated as the mean OOP cost health plan members today are paying more on a per-claim basis for these products than in 2004. The newer benefit designs, such as high-deductible health plans with savings options, are likely contributing to the increase in mean member OOP expenditures. However, the mean member contribution per claim still remains less than 4% of the total AWP price paid, with the insurer absorbing the bulk of the pharmaceutical manufacturers' price increases. The wide variance between the mean and median member OOP cost per claim found in our analyses indicates that the OOP cost distribution is skewed (i.e., a small portion of members is paying high OOP cost, especially in the first quarter of each year) (Figure 4 ). Further analysis of the distribution in OOP cost is needed to determine the percentage of members paying high OOP cost and the amount being paid.
Price inflation for self-injectable MS drugs has pushed the average price per claim up 53% in 3.5 years, from an average $1,381 in first-quarter 2004 to $2,119 in third-quarter 2007 (Table 3) . Since utilization has remained fairly constant over this period, drug cost PMPM for these self-injectable MS drugs has risen 57%, from $1.11 PMPM in first-quarter 2004 to $1.74 PMPM in third-quarter 2007, driven by price inflation. Meanwhile, median member OOP cost and average member cost-share have changed little over this 3.5-year period. It is unclear whether insurers will continue to absorb the price increases or further shift the burden to their members. Further investigation into the relationship between member OOP expenses and utilization is necessary, as is keeping a watchful eye on price inflation.
